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STUDY OBJECTIVE Patients with schizophrenia are known to have higher rates of metabolic disease than
the general population. Contributing factors likely include lifestyle and atypical antipsychotic (AAP)
use, but the underlying mechanisms are unknown. The objective of this study was to identify meta-
bolomic variability in adult patients with schizophrenia who were taking AAPs and grouped by fast-
ing insulin concentration, our surrogate marker for metabolic risk.
DESIGN Metabolomics analysis
PARTICIPANTS Ninety-four adult patients with schizophrenia who were taking an AAP for at least
6 months, with no changes in their antipsychotic regimen for the previous 8 weeks, and who did
not require treatment with insulin, participated in the study. Twenty age- and sex-matched nonob-
ese (10 subjects) and obese (10 subjects) controls without cardiovascular disease or mental health
diagnoses were used to match the body mass index (BMI) range of the patients with schizophrenia
to account for metabolite concentration differences attributable to BMI.
MEASUREMENTS AND MAIN RESULTS Existing serum samples were used to identify aqueous metabolites (to
differentiate fasting insulin concentration quartiles) and fatty acids with quantitative nuclear magnetic
resonance and gas chromatography methods, respectively. To exclude metabolites from our pathway
mapping analysis that were due to variability in weight, we also subjected serum samples from the non-
obese and obese controls to the same analyses. Patients with schizophrenia had a median age of 47.0
years (interquartile range 41.0–52.0 years). Using a false discovery rate threshold of less than 25%, 10
metabolites, not attributable to weight, differentiated insulin concentration quartiles in patients with
schizophrenia and identified variability in one-carbon metabolism between groups. Patients with
higher fasting insulin concentrations (quartiles 3 and 4) also trended toward higher levels of saturated
fatty acids compared with patients with lower fasting insulin concentrations (quartiles 1 and 2).
CONCLUSION Our results illustrate the utility of metabolomics to identify pathways underlying variable fast-
ing insulin concentration in patients with schizophrenia. Importantly, no significant difference in AAP
exposure was observed among groups, suggesting that current antipsychotic use may not be a primary
factor that differentiates middle-aged adult patients with schizophrenia by fasting insulin concentration.
KEY WORDS adverse drug reactions, Insulin, antipsychotics.
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Cardiovascular disease (CVD) is a major cause
of premature mortality in patients with
schizophrenia.1, 2 It is not fully understood why
these patients experience more CVD than the
general population, but medication is likely an
important contributing factor. Atypical antipsy-
chotics (AAPs), in particular, have been identi-
fied as culprits because of their tendency to
cause adverse metabolic effects such as weight
gain, dyslipidemias, and diabetes mellitus. These
adverse events are consistent with components
of metabolic syndrome (MetS),3 a well-known
risk factor for CVD. In 2004, the American Psy-
chiatric Association collaborated with the Ameri-
can Diabetes Association and others to describe
monitoring recommendations for the develop-
ment of MetS in AAP users.4 Unfortunately,
these recommendations are not often followed in
practice,5 stressing a need for improved under-
standing of the underlying mechanisms of MetS
to develop more precise approaches for monitor-
ing and preventing adverse metabolic side
effects.
An alternative option for assessing CVD risk in
AAP users is fasting insulin concentration
associated with insulin resistance and future
development of prediabetes and diabetes.6, 7 The
development of insulin resistance was also
observed before weight gain in response to
AAPs,8, 9 and it is considered an essential compo-
nent of the definition of MetS.10 Therefore, we
reasoned that a hypothesis-generating metabolo-
mics study would identify unique metabolite sig-
natures associated with variable fasting insulin
concentrations in AAP users with schizophrenia
and provide added insight on the biological path-
ways differentiating patients with schizophrenia
who have variable CVD risk. We also expected to
see greater exposure to AAPs in general and
increased use of more obesogenic AAPs (such as
clozapine and olanzapine) in participants with
relatively higher fasting insulin concentrations.
We therefore conducted a metabolomics analysis
of existing serum samples from adult patients
with schizophrenia, grouped by log-transformed
fasting insulin concentration quartiles, using
quantitative 1D-1H-nuclear magnetic resonance
(NMR) spectroscopy and a gas chromatography
assay for the detection of fatty acids (FAs).
Because the median body mass indexes (BMIs) of
patients in each fasting insulin quartile were dif-
ferent, we also assayed existing serum samples
from obese (BMI 30 kg/m2 or higher) and nonob-
ese (BMI lower than 30 kg/m2) subjects without
CVD or mental health diagnoses who were
matched to the schizophrenia cohort by sex, age,
and BMI range to account for metabolite concen-
tration differences attributable to BMI. AAP use
was compared across quartiles with two
approaches: normalizing exposure using chlor-
promazine equivalents; and comparing percent-
ages of patients using AAPs divided into three
groups based on their propensity to cause weight
gain.
Methods
Study Design, Patients, and Data Collection
For this metabolomics pilot study, existing
serum samples from patients with schizophrenia
were selected from a large ongoing cross-sec-
tional study on CVD risk in schizophrenia.
Inclusion criteria for the parent study were 18–
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90 years of age; Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition,11 diagnosis
of schizophrenia, schizophreniform disorder,
schizoaffective disorder, or psychotic disorder
not otherwise specified; and taking an antipsy-
chotic for at least 6 months with no changes in
antipsychotic regimen for the previous 8 weeks.
Exclusion criteria were inability to give informed
consent, presence of diabetes mellitus type 2
diagnosis before initiation of antipsychotic ther-
apy, and an active substance abuse diagnosis.
For inclusion in this pilot study, patients had to
be taking an AAP and not require treatment with
insulin.
For the parent study, anthropometric mea-
surements and venipuncture were performed at
the University of Michigan Clinical Research
Unit (MCRU; http://www.michr.umich.edu/ser
vices/mcru). A dietician collected information on
dietary recall from all participants, and informa-
tion on past and current medication use was col-
lected by the study team. The parent study
protocol was approved by the University of
Michigan institutional review board (IRBMED
HUM00017774) and the IRBs of the Washtenaw
County Health Organization, the Detroit-Wayne
County Community Mental Health Agency, and
the Ann Arbor Veterans Affairs Medical Center.
The study was performed in accordance with the
ethical standards of the Helsinki Declaration of
1975 (as revised in 1983).
AAP Exposure Standardization and Risk
Categories
Atypical antipsychotic exposure was standard-
ized between groups using formulas previously
described12 to calculate chlorpromazine equiva-
lents for aripiprazole, clozapine, olanzapine,
quetiapine, risperidone, and ziprasidone. The
equations for calculating chlorpromazine equiva-
lents for paliperidone, iloperidone, and lurasi-
done were obtained from a previous study.13
Because AAPs are known to have a varying
propensity to cause adverse metabolic side
effects, medication use was further described by
risk group, as follows: high (olanzapine or cloza-
pine), moderate (quetiapine, risperidone, iloperi-
done, or paliperidone), and low (aripiprazole,
ziprasidone, and lurasidone).14–17 When partici-
pants were taking more than one AAP, the medi-
cation with the highest risk was used to group
the participant into a medication risk category.
Antipsychotic polypharmacy was also described
as the use of two to three antipsychotics (typical
or atypical).
Controls
Existing serum samples from a cohort of
patients who were enrolled in the Univer-
sity of Michigan’s Weight Management Program
(NCT02043457)18, 19 and technical replicate
serum samples from healthy subjects who were
recruited from the Claude D. Pepper Older
Americans Independence Center Research Par-
ticipant Program at the University of Michigan’s
Geriatric Center18–20 were used as controls. To
be included in the weight management program,
participants were required to meet a minimum
BMI of 32 kg/m2 with at least one comorbidity
or a BMI of at least 35 kg/m2.18, 19 For this pilot
study, these additional exclusion criteria were
applied: present CVD or diabetes, psychiatric
disorder, and use of weight-potentiating medica-
tion such as steroids. From these cohorts, two
control groups (without CVD or mental health
diagnoses) were formed to match the range of
BMI of the patients with schizophrenia. The first
group was selected to have a mean BMI lower
than 30 kg/m2 (nonobese) and the second
higher than 30 kg/m2 (obese). All were matched
to the schizophrenia cohort for sex and age
range. The protocols under which the control
data were acquired were also approved by
IRBMED (obese controls: HUM00030088, non-
obese controls: HUM00038122), and all partici-
pants in the schizophrenia and BMI control
groups provided informed consent.
Serum Sample Preparation and Fasting Insulin
Assay
Whole blood from fasting patients with
schizophrenia was collected by direct venipunc-
ture into additive-free collection tubes, allowed
to coagulate for at least 30 minutes and then
centrifuged (2500 9 g for 10 min) to generate
serum. Serum was aliquoted into vials for stor-
age (80°C) until time of assay except for expo-
sure to one freeze-thaw cycle for an analysis
related to the parent study. The blood collec-
tions from obese and nonobese participants were
similar and were previously described.18–20 For
this pilot study, an additional aliquot (minimum
of 125 µL) of frozen serum from participants
with schizophrenia and negative controls was
sent to the Michigan Diabetes Research Center
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to assess fasting insulin concentration by
radioimmunoassay.
Before the time of assay, serum samples were
randomized into batches of 10 for extraction
and NMR analysis. At the time of assay, samples
were subjected to a water (H2O)/methanol
(MeOH):chloroform (CHCl3) extraction as previ-
ously described.21, 22 The dried CHCl3 fraction
was transported to the Michigan Comprehensive
Regional Metabolomics Core (MRC2) for FA
analysis.
Quantitative 1D-1H-NMR Metabolomics and Gas
Chromatography to Detect Free FA
The 1D-1H-NMR spectra of the H2O/MeOH
fraction of each sample were acquired at the
University of Michigan’s NMR Biochemical Core
Laboratory on a Varian (now Agilent Inc., Santa
Clara, CA, USA) 11.74-T (500 MHz) NMR spec-
trometer. This process was previously described
in detail,23 and further description of the meth-
ods are provided in the supplementary informa-
tion in addition to a representative NMR
spectrum (Figure S1). The CHCl3 fractions con-
taining the lipids of the serum samples were
assayed for FA content, using an Agilent 5890
gas chromatograph with an Agilent HP 88 col-
umn, by the MRC2 using a modified technique
previously described.24 A representative gas
chromatogram can also be found in the support-
ing information (Figure S2).
Statistical and Pathway Analysis
For the patients with schizophrenia, groups
were created by separating their log-transformed
fasting insulin concentrations into quartiles. The
quantified metabolomics data sets were trans-
formed and scaled in MetaboAnalyst v.3.0
(http://www.metaboanalyst.ca/) to achieve nor-
mal distribution in preparation for parametric
statistical analyses.25, 26 The FA data were ana-
lyzed as relative percentage of total to account
for different initial sample volumes. Normalized
data were analyzed by analysis of variance
(ANOVA) with a Tukey-Kramer post hoc test,
and demographic and clinical data were com-
pared with Wilcoxon, ANOVA, or v2 tests, as
appropriate in JMP Pro v.11 (SAS Institute, Inc.,
Cary, NC, USA). For the control participants,
metabolite mean concentrations were compared
between BMI groups with an unpaired Student t
test. For all normalized mean metabolite com-
parisons, Welch’s corrections were applied when
variance between groups was not similar. Daily
AAP exposure was calculated by translating total
AAP medication dose into chlorpromazine
equivalents.12, 13 To control for multiple com-
parisons, a false discovery rate (FDR) of the
resulting post hoc p values was calculated for
each metabolite using the method previously
described.27 Metabolites with an FDR lower than
25% were used in pathway analysis by Metscape
(http://metscape.ncibi.org/),28 a plug-in for
Cytoscape (http://www.cytoscape.org/). Figures
were constructed using R (https://www.r-project.
org/).29
Results
Participant Characteristics
Patients with Schizophrenia
Ninety-four patients with schizophrenia were
included in this study. Patients were grouped by
log-transformed insulin concentration quartile
that was different across all four quartiles (Fig-
ure 1A). Of note, several metabolic parameters
were significantly different among schizophrenia
groups (p<0.05) including BMI (Figure 1C) and
MetS diagnosis (Table 1). Cumulative average
AAP dose exposure was available for 96.8% (91/
94 patients) and was not significantly different
among groups, and neither was the variability
among quartiles when examining AAP risk
groups. With respect to polypharmacy, the rates
were not significantly different among quartiles
(Table 1). A total of six patients were using a
typical and atypical antipsychotic medication
combination regimen: five were using fluphena-
zine and one was using haloperidol, in addition
to an AAP. The participant taking haloperidol
was also using olanzapine, and four participants
taking fluphenazine were using moderate-risk
AAPs; one was taking ziprasidone. Risk category
was not modified for participants based on typi-
cal antipsychotic use. Time since schizophrenia
diagnosis was assessed by group as a surrogate
marker for approximate length of exposure to
antipsychotics. This measure was also not signif-
icantly different between groups.
Obese and Nonobese Control Subjects
The median age of the 10 obese control par-
ticipants was 46.5 years (interquartile range
[IQR] 45.0–49.0 years) and 46.5 years (IQR
41.8–50.3 years) for the 10 nonobese
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participants (p=0.704). Median log-transformed
fasting insulin values were 1.13 lU/ml (IQR
1.05–1.17 lU/ml) and 1.12 lU/ml (IQR
1.02–1.32 lU/ml) for the nonobese and obese
controls, respectively (p=0.500) (Figure 1B).
The median BMI for the nonobese and obese
controls was 25.3 kg/m2 (IQR 20.9–27.0 kg/m2)
and 34.7 kg/m2 (IQR 33.4-36.7 kg/m2), respec-
tively (p<0.001) (Figure 1D).
Quantitative 1H-NMR Metabolomics and
Pathway Analysis
Thirty-six metabolites were identified and
quantified by 1H-NMR in all serum samples. Of
these, 13 1H-NMR detected metabolites differen-
tiated (FDR less than 25%) the insulin quartiles
based on the ANOVA p value (Table 2). To
identify associated metabolic pathways, these
compounds were entered into Metscape (http://
metscape.ncibi.org/), an open-source bioinfor-
matics platform that permits the visualization
and identification of associated metabolic path-
ways.28 Among resulting pathways, one-carbon
metabolism, and glycine, serine, alanine, and
threonine metabolism were represented by at
least three metabolites.
If metabolites were different (FDR less than
25%) between obese and nonobese controls,
they were considered to be attributable to BMI
and were removed from the Metscape analysis.
However, if differentiating metabolites between
the obese and nonobese controls were also rep-
resented as a differentiating metabolite in the
schizophrenia analysis, but their concentrations
trended in the opposite direction as weight (e.g.,
glycine), they were not removed from the Mets-
cape analysis (Table 2). After this adjustment,
we determined that differences in the concentra-
tions of the remaining seven metabolites were
influenced by insulin concentration (Fig-
ures 2A–N). Metscape mapping of these com-
pounds generated a one-carbon metabolism
pathway that involved three of these metabolites:
serine, glycine, and taurine (Figure 3). Support-
ing information includes all differentiating
metabolites (FDR less than 25%) from the con-
trol analyses (Table S1) and all pathways that
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Figure 1. Box and whisker plots of log-transformed fasting insulin concentration (Log(FI)), measured as mU/ml, and body
mass index (BMI) by quartile for the patients with schizophrenia (A and C, respectively) and by BMI group for the controls
(B and D, respectively). The crossbar of the box indicates the median, the box spans the interquartile range, and the
whiskers indicate the entire data range, with outliers identified as individual points. The schizophrenia quartiles (Q1–4) are
designated by log(FI). BMI was significantly different among all of the schizophrenia groups (p<0.01) with the exceptions of
Q2 and Q3. Log(FI) was significantly different among all schizophrenia groups (p<0.05). BMI was significantly different
between the two obese and nonobese control groups (p<0.001). The BMI of the obese control group was significantly greater
than the BMI of schizophrenia quartiles Q1 (p<0.001) and Q2 (p=0.003). The BMI of the nonobese controls was significantly
less than that of Q2 (p=0.003), Q3 (p<0.001), and Q4 (p<0.001). Log(FI) was significantly different between the BMI control
groups and all the schizophrenia quartiles, with the exception of the obese controls and Q2. Log(FI) was not significantly
different between the nonobese and obese controls. Wilcoxon tests were used to compare BMI and fasting insulin
concentrations among groups, and post hoc Wilcoxon each pair analyses were completed to identify differences within
groups. For example, a Wilcoxon test noted that fasting insulin was significantly different between schizophrenia quartiles,
and the post hoc tests identified that all quartiles varied significantly from each other by fasting insulin concentration.
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were mapped with Metscape (Table S2). The 1H-
NMR and FA data sets are freely accessible via
the Metabolomics Workbench (http://www.me
tabolomicsworkbench.org/).
Quantitative Fatty Acid Analysis
A total of 23 serum FAs were identified and
quantified. In the schizophrenia cohort, signifi-
cant differences were apparent in several satu-
rated FAs, such as 16:0 (palmitic acid), 14:0
(myristic acid), 24:0 (lignoceric acid), and the
unsaturated essential FA 18:2 (linoleic acid).
Three FAs, 16:0, 18:2, and 24:0, were not asso-
ciated with BMI and differentiated the four insu-
lin quartiles of the schizophrenia cohort
(Table 2 and Figures 4A–F).
Discussion
We conducted a metabolomics analysis of
serum samples from patients with schizophrenia
who were taking AAPs and analyzed the results
based on their fasting insulin concentration
quartiles. This approach permitted the detection
of unique metabolic signatures associated with
variable fasting insulin concentrations and
demonstrated the utility of fasting insulin con-
centration as a biochemical anchor for the
metabolic phenotyping of this population. We
discuss the importance of perturbed one-carbon
metabolism as a contributing factor to cardiovas-
cular risk in patients with schizophrenia. We
suggest that analyzing CVD risk by fasting insu-
lin concentration in this population provides
insight into metabolic variances between AAP
users because no significant differences were
found in average daily AAP exposure or higher
metabolic risk AAP use between the insulin
quartiles. Furthermore, these findings were not
solely attributable to differences in BMI.
Among the affected pathways identified from
differentiating metabolites by Metscape, the folate
cycle and methionine and cysteine metabolism
intersect through their involvement in one-carbon
metabolism that is essential for DNA methylation,
purine synthesis, and homocysteine metabolism
(Figure 3). In our cohort, concentrations of the
methyl donors glycine and serine trended higher
in the lower insulin quartiles. This suggests
increased availability of one-carbon groups avail-
able for the folate cycle. In addition, serine is used
in the formation of cystathionine from homocys-
teine, ultimately leading to production of the
endogenous antioxidant glutathione. This is
important because elevations in homocysteine
have repeatedly been linked to CVD through
mechanisms that are not yet understood.30, 31
Perturbed one-carbon metabolism was also
implicated in CVD risk in patients with
Table 2. Serum Metabolites and Fatty Acids Identified and Quantified
KEGG ID ANOVA p value False discovery rate (%) Post hoc resultsa
Metabolites
Glutamate C00302 0.0001 0.36 Q3 > Q1; Q3 > Q2; Q4 > Q1; Q4 > Q2
Acetate C00033 0.0057 10.26 Q2 > Q4; Q3 > Q4; Q1 > Q4
Tyrosine C00082 0.0129 15.48 Q4 > Q1
3-hydroxybutyrate C01089 0.0269 16.87 Q1 > Q4
Carnitine C00487 0.0269 16.87 Q2 > Q4
Glycine C00037 0.0286 16.87 Q1 > Q4
Alanine C00133 0.0328 16.87 Q3 > Q1
Serine C00065 0.0536 22.76 Q3 > Q4
Creatine phosphate C02305 0.0690 23.84 Q3 > Q4
Valine C00183 0.0842 23.84
Taurine C00245 0.0862 23.84
Proline C00148 0.0891 23.84
Leucine C00123 0.0927 23.84
Fatty acids
14:0 C06424 <0.0001 0.02 Q3 > Q1; Q4 > Q1; Q2 > Q1
16:1 C08362 <0.0001 0.02 Q3 > Q1; Q4 > Q1; CQ3 > Q2; Q4 > Q2
18:2 C01595 0.0008 0.61 Q1 > Q4; Q1 > Q3; Q2 > Q4
16:0 C00249 0.0025 1.44 Q4 > Q1
24:0 C08320 0.0349 16.05
Serum metabolites detected by 1H-nuclear magnetic resonance and fatty acids detected with gas chromatography were identified as differenti-
ating patients with schizophrenia across insulin concentration quartiles (false discovery rate less than 25%). Metabolites in italics and bold-
face were those determined to be associated with body mass index (see text).
ANOVA = analysis of variance; Q = quartile.
aPost hoc results were determined to be significant when Tukey-Kramer p values were less than 0.05.
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schizophrenia.32 Our group has observed
decreased methylation capacity and worsening
endothelial function in schizophrenia patients
with genetic polymorphisms in folate cycle
enzymes associated with hyperhomocysteine-
mia.33, 34 We also found that supplemental
folate administration improved methylation
capability and endothelial function in
schizophrenia patients taking AAPs.35 In addi-
tion, the folate cycle is intimately tied to FA
metabolism because it is needed to contribute
methyl groups for carnitine methylation and FA
chain elongation and desaturation.36 It was pro-
posed in 201432 that the complex relationship
between FAs and the folate cycle in CVD and
psychiatric disease could be described as oxida-
tive stress leading to the one-carbon cycle
spending proportionally more time on transsul-
furation compared with methylation. This could
decrease available methyl groups, resulting in
less FA chain elongation and desaturation. We
observed metabolite concentration changes that
may agree with this hypothesis: saturated FAs
were elevated in schizophrenia patients with
higher fasting insulin concentrations (e.g., Q3
and 4), whereas patients with lower fasting insu-
lin concentrations (e.g., Q1 and 2) had higher
concentrations of methyl-donating amino acids.
This pattern of elevation in saturated FAs was
also observed in settings of CVD37 in patients
without mental health disorders.
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Figure 2. Box and whisker plots of normalized serum
metabolite concentrations detected and quantified by 1H-
nuclear magnetic resonance (A–N) in the schizophrenia
quartiles (A, C, E, G, I, K, and M) and body mass index
(BMI) controls (B, D, F, H, J, L, and N). Metabolites shown
in the schizophrenia column are those that differentiated
insulin quartiles (analysis of variance false discovery
rate < 25%) that were determined to be independent of
BMI (see text). This was determined if the Student t test
results comparing the same normalized metabolite
concentrations between the BMI control groups was not
significant or the metabolite concentrations trended in
opposite directions with weight in the BMI controls and
schizophrenia groups (e.g., glycine). In the patients with
schizophrenia, glycine (A) concentration trended lower but
was increased in obese BMI controls compared with
nonobese BMI controls (B). Serine (C and D), taurine (E
and F), carnitine (G and H), and 3-hydroxybutyrate (I and
J) concentrations followed the same trends. Acetate and
creatine phosphate concentrations trended lower in
patients with schizophrenia (K and M) but were not
significantly different between nonobese and obese controls
(L and N). Asterisks indicate metabolite concentrations in
the schizophrenia group that were significantly different
between quartiles (Tukey-Kramer post hoc p<0.05) or
between BMI controls (Student t test p<0.05).
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Insulin concentration is known to be associ-
ated with weight, thus complicating our analysis.
Both weight and fasting insulin concentration
were significantly different between quartiles. To
account for weight variability, we used two
groups of control subjects, obese and nonobese
participants without CVD or any psychiatric
diagnosis, and completed the same metabolo-
mics assays for this cohort. Importantly, fasting
insulin concentration was not significantly dif-
ferent between groups. As such, we attributed
differences in metabolite and FA concentrations
between the BMI control groups as those that
were primarily due to differences in weight. We
used these results to interpret the metabolomics
data from the schizophrenia cohort’s insulin
concentration quartiles. With respect to FAs,
palmitic acid (16:0), linoleic acid (18:2), and lig-
noceric acid (24:0) remained uniquely altered in
schizophrenia patients. Palmitic acid trended
upward in Q3 and 4, whereas linoleic and ligno-
ceric acids trended lower. Of these FAs, linoleic
acid (18:2) is an essential FA and reflects vari-
able diet. This suggests that linoleic acid intake
trended inversely with fasting insulin in the
schizophrenia cohort.
To test the rigor of our analysis, we separated
the schizophrenia participants into two groups
(obese and nonobese) to act as their own con-
trols for BMI variability and completed the same
analyses performed for the BMI controls without
psychiatric diagnoses or CVD. The table of dif-
ferentiating metabolites from this analysis is pro-
vided in the supplement (Table S3). No
differentiating 1H-NMR metabolites were com-
mon to both the fasting insulin quartile analysis
and the BMI analysis that were not already iden-
tified as associated with BMI by the control anal-
ysis (and indicated in Table 2). After a similar
comparison of the FA differentiating the
schizophrenia insulin quartiles and BMI groups,
palmitic acid was the only remaining FA associ-
ated with fasting insulin concentration and not
BMI. Unlike the BMI controls used for the pri-
mary analysis, log-transformed fasting insulin
concentration differentiated the schizophrenia
groups separated by obese or nonobese BMI
classification (Wilcoxon test p<0.001), making
Figure 3. Simplified schematic diagrams of one-carbon metabolism. Arrows depict trend of metabolite concentration with
increasing body mass index (BMI). Solid (green) arrows indicate differentiating metabolites whose concentrations trended
inversely with weight among the schizophrenia quartiles. Open (red) arrows indicate differentiating metabolites whose
concentrations increased with weight among the BMI controls. The inverse relationship between the concentration of these
metabolites with BMI indicates that variability in one-carbon metabolism is not solely due to weight. THF = tetrahydrofolate.
[Color figure can be viewed at wileyonlinelibrary.com]
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interpretation of these results less straightfor-
ward. Although not confirmatory, these results
indicate that the metabolite variability of the
schizophrenia cohort is neither entirely due to
differences in BMI nor to AAP exposure between
the insulin quartiles.
We chose to describe AAP use among insulin
quartiles in the schizophrenia cohort with two
different approaches: comparing the proportion
of patients using medications at three different
levels of metabolic risk, and normalizing average
daily AAP exposure using chlorpromazine
equivalents. This was done because AAPs have a
variable propensity to cause metabolic adverse
effects, and no AAP is likely free from this
risk.38 Neither measure was significantly differ-
ent among schizophrenia quartiles (Table 1).
This was an interesting finding because it sug-
gests that current AAP use may not impact fast-
ing insulin concentration in this population. The
lack of difference in AAP exposure among quar-
tiles may be due to the similar length of time
since schizophrenia spectrum diagnosis
(Table 1). This could reflect previous exposure
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Figure 4. Box and whisker plots of normalized concentrations of individual fatty acids (FAs) by percentage total that
differentiated insulin quartiles in patients with schizophrenia (analysis of variance false discovery rate < 25%; A, C, and E)
but not body mass index (BMI) (B, D, and F). This was determined if the Student t test p values comparing the same
normalized FA concentrations between the BMI control groups were not significant or if the FA concentrations were not
associated with weight in the BMI schizophrenia groups. Asterisks indicate FAs that were significantly different (Tukey-
Kramer post hoc p<0.05) between quartiles. Q = quartile.
METABOLITE PROFILES OF ANTIPSYCHOTIC USERS Ward et al 647
to a variety of antipsychotic treatment trials.
Because many patients could not recall an in-
depth account of past antipsychotic exposure, it
was not possible to assess the impact of the
duration of treatment on the metabolome. Previ-
ous research suggests that duration of exposure
to AAP influences the metabolome early in
schizophrenia treatment, but it is still unclear
how drug use influences the metabolome
and metabolic risk after several antipsychotic tri-
als. For example, a lipidomics study39 noted sig-
nificant changes in lipid profiles following only
2 weeks of drug therapy in patients experiencing
their first episode of schizophrenia, and another
study40 found metabolites associated with future
weight gain in patients with first-episode psychosis
followed over 1 year.
The lack of a relationship between fasting
insulin concentration and current AAP exposure
is interesting, particularly given the association
between AAP use and the development of
adverse metabolic events.41 This leaves unan-
swered an important question regarding how
essential the timing and duration of AAP expo-
sure is to encouraging the disruption of glucose-
insulin homeostasis. In the future, it will be
important to capture changes in the metabolome
before and for an extended period of time after
AAP initiation and medication switches. It will
also be necessary to have studies adequately
powered to allow for further group separation
by sex because research in 2014 showed this to
be an important factor in determining changes
in folate cycle metabolites following antipsy-
chotic administration.42
Despite these intriguing findings, we
acknowledge that this was an exploratory study
with several limitations. First, this was a retro-
spective investigation that used existing blood
samples from a relatively small sample size,
preventing us from drawing conclusions about
AAP-induced changes on the metabolome. In
addition, the use of NMR-based metabolomics
results in significantly fewer metabolites than
approaches using detection methods based on
mass spectrometry. We possibly could have
identified additional biochemical pathways asso-
ciated with variability in fasting insulin concen-
tration with the use of a more sensitive
platform like liquid chromatography–mass spec-
trometry. However, for this preliminary study,
the advantages of quantitative NMR metabolo-
mics outweighed this option because NMR is
routinely quantitative, highly reproducible, and
nondestructive to the sample. Use of this
approach will also direct the selection of more
sensitive targeted assays for future studies.
Another limitation of the study stems from the
liberal FDR of less than 25% that is consistent
with exploratory genetics analyses43 but
increases the likelihood of type 1 error.
Conclusion
Our metabolomics analyses identified differ-
ences in concentrations of metabolites associated
with variable one-carbon metabolism (glycine,
serine, and taurine) among fasting insulin con-
centration quartiles of a schizophrenic cohort:
specifically, that fasting insulin concentration
trended inversely with increased methylation
capability. We also found that patients with
schizophrenia who had higher insulin concentra-
tions (e.g., Q3 and 4) had higher levels of the sat-
urated FA 16:0 (palmitic acid). These findings
appeared to be independent of current AAP use
and demonstrated the utility of anchoring meta-
bolomics studies to fasting insulin concentration
as a measure of metabolic risk in this population,
as compared with MetS diagnosis that is observ-
able after fasting insulin concentration elevations.
In aggregate, these results have implications for
furthering knowledge about the mechanisms
involved in the development of CVD in schizo-
phrenic patients because loss of, or a decline in,
methylation capability may be associated with
endothelial dysfunction. Future studies will need
to include a targeted prospective metabolomics
approach with a more stringent FDR. Ultimately,
understanding the metabolic consequences of
AAPs across all phases of schizophrenia and how
AAPs impact variable baseline risk for CVD will
allow for safer medication use through improved
metabolic monitoring and the design of more
precise treatment regimens.
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